Trials / Conditions / Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

21 registered clinical trials studyying Extensive-stage Small Cell Lung Cancer (ES-SCLC) — 19 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stag NCT07339059	Bindu R Potugari	Phase 2
Not Yet Recruiting	DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizum NCT07472517	Boehringer Ingelheim	Phase 3
Not Yet Recruiting	Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Smal NCT07501169	Sichuan University	Phase 2
Recruiting	Iadademstat + SBRT With Atezo in ES-SCLC NCT07113691	Yale University	Phase 1
Recruiting	A Study of Ivonescimab in First-Line ES-SCLC NCT07245446	Akeso	Phase 2
Recruiting	Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Trea NCT07425795	Chongqing University Cancer Hospital	Phase 2
Not Yet Recruiting	Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer NCT07106528	Peking Union Medical College Hospital	Phase 2 / Phase 3
Not Yet Recruiting	Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell L NCT07061535	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Not Yet Recruiting	Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer NCT07063407	Shanghai Hansoh Biomedical Co., Ltd	Phase 1
Not Yet Recruiting	Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cel NCT06909383	Guangzhou Institute of Respiratory Disease	Phase 2
Not Yet Recruiting	Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line E NCT06961201	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 3
Recruiting	Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage NCT06801834	Gilead Sciences	Phase 3
Recruiting	Second-line Immunotherapy for ES-SCLC NCT06853678	Tianjin Medical University Cancer Institute and Hospital	N/A
Recruiting	Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC NCT06838208	Anhui Provincial Cancer Hospital	Phase 2
Recruiting	Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer NCT06758700	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES NCT06663098	Gruppo Oncologico Italiano di Ricerca Clinica	Phase 2
Withdrawn	ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer NCT06052423	Hansoh BioMedical R&D Company	Phase 2
Not Yet Recruiting	A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell NCT06530797	Shanghai Pulmonary Hospital, Shanghai, China	—
Active Not Recruiting	Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer NCT06748495	Hunan Cancer Hospital	—
Recruiting	A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587	IDEAYA Biosciences	Phase 1
Recruiting	Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage NCT07070011	Shanghai Chest Hospital of Shanghai Jiao Tong University	—